Genmab — Marts 2019
-
A/B har været største køber i et pænt stykke tid. I dag er der en eller flere fra gruppen som hælder ud.
-
Lidt mystisk bare at sælge ned gennem hylderne på den måde.¨
-
Den har de brugt før. F.eks. forleden dag.
-
Media Release
Copenhagen, Denmark, March 11, 2019
Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Marisol Peron has
been appointed Corporate Vice President, Communications and Investor
Relations, effective March 11, 2019. Ms. Peron will be responsible for the
strategic management of both internal and external communications and
investor relations efforts for Genmab. Andrew Carlsen, who recently joined
the company as Senior Director Investor Relations, continues to be the
contact point -
for investors and analysts.
Ms. Peron joins Genmab with over 20 years experience in corporate
communications in the life sciences industry. She brings with her expertise
in the creation, implementation and management of both internal and
external corporate communications strategies, having previously spent 17
years at Sanofi, where she led communications for the vaccines division in
North America and held various communications roles for Sanofis oncology,
cardiovascular and diabetes business u -
units. Most recently, Ms. Peron served
as the Vice President of Communications for North America at Ipsen
Biopharmaceuticals.Ms. Peron replaces Rachel Curtis Gravesen, who will pursue new
opportunities elsewhere, but will be available during a short transition
period. -
Langers Skarpe Aktietips
Er de professionelle på vej til at sikre sig et solidt årsafkast ved allerede at hjemtage gevinster? Det styrende amerikanske aktiemarked faldt i denne uge under det psykologisk vigtige 200 dages glidende gennemsnit, som markerer forskellen mellem en langsigtet optrend og en langsigtet nedtrend. Efter en tur under, sluttede de amerikanske aktier lige netop på pejlemærket […]
Økonomisk Ugebrev (ugebrev.dk)
-
Hvad er det for en dansk small cap de
henviser til -
Man skal som altid passe på med overskrifter. Fra den omtalte artikel "Our goal with this article is not to criticize the MAIA trial, make statements on how the results should be interpreted or dictate the standard-of-care treatment for newly diagnosed MM"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind